InvestSMART

BlinkLab Limited (ASX: BB1) - Share Price

Current share price for BB1 : $0.575 0.015 (2.54%)+

BlinkLab Limited (BB1) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It , a company founded by neuroscientists at Princeton University, over the past several years has fully developed a smartphone based diagnostic platform for autism and ADHD. The Company's most advanced product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old.

BB1 General Information +

ASX Code BB1
Website N/A
Industry/Sector Health Care Technology
Market Cap ($M) 101
BB1 Share Price $0.575
Day High $0.585
Day Low $0.575
Last Close $0.590
BB1 Share Price Movement $0.02 ( 2.54% )
Prices as at 16:30, 3 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

BlinkLab Limited (BB1) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from BlinkLab Limited (BB1) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

BlinkLab Limited (BB1) price-sensitive announcements

BB1 - Quarterly Activities/Appendix 4C Cash Flow Report
BlinkLab Limited’s Quarterly Activities Report and Appendix 4C for the quarter ended 30 Se
BlinkLab Limited (BB1)
29 Oct 2026 | 9:08 AM
BB1 - European ADHD Study Delivers Positive Results
BlinkLab Limited, trading as BB1 on the ASX, announced positive results from their Europea
BlinkLab Limited (BB1)
5 Aug 2026 | 9:15 AM
BB1 - Trading Halt
BlinkLab Limited (ASX: BB1) requested a trading halt for its securities on 3 August 2026,
BlinkLab Limited (BB1)
3 Aug 2026 | 9:24 AM
BB1 - 2026 Annual Report & Appendix 4E
The 2026 Annual Report & Appendix 4E for BlinkLab Limited outlines the financial performan
BlinkLab Limited (BB1)
31 Jul 2026 | 2:26 PM

BlinkLab Limited (BB1) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
BlinkLab Limited (BB1)
ORDINARY FULLY PAID
 Health Care $101 Quarterly Activities/Appendix 4C Cash Flow Report 29 Oct 2026 9:08AM $0.630 $0.575 fallen by 8.73%
BlinkLab Limited (BB1)
ORDINARY FULLY PAID
 Health Care $101 Commencement of Nationwide Autism Screening in Morocco 22 Oct 2026 9:39AM $0.620 $0.575 fallen by 7.26%
BlinkLab Limited (BB1)
ORDINARY FULLY PAID
 Health Care $101 BB1 to Present at Simons Foundation and ThinkEquity in NYC 13 Oct 2026 9:13AM $0.620 $0.575 fallen by 7.26%
BlinkLab Limited (BB1)
ORDINARY FULLY PAID
 Health Care $101 BB1 to Present at Spark Plus Aussie Equities Day Singapore 9 Oct 2026 9:38AM $0.645 $0.575 fallen by 10.85%
BlinkLab Limited (BB1)
ORDINARY FULLY PAID
 Health Care $101 BB1 to Present at NSSpain - Apple Developer Conference 17 Sep 2026 8:51AM $0.680 $0.575 fallen by 15.44%
BlinkLab Limited (BB1)
ORDINARY FULLY PAID
 Health Care $101 Change of Director's Interest Notice x3 11 Sep 2026 2:57PM $0.700 $0.575 fallen by 17.86%

BB1 Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$7.22 -$5.50 -0.50% 0.00 0.00 0.00% 0.0%
2025A -$5.71 -$5.60 112.60% 0.00 0.00 0.00% 0.0%
2024A -$1.75 -$2.60 283.80% 0.00 0.00 0.00% 0.0%

BB1 Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
4DMedical Limited (4DX) $1,469M 1.7823 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Artrya Limited (AYA) $453M -0.0450 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
BlinkLab Limited (BB1) $109M -0.0054 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Pro Medicus Limited (PME) $20,497M 1.3034 -0.2811 0.2395 77.3659 107.6189 86.8218 0.35% 0.47% 0.58%

BB1 Directors

Name Position Start Date
Dr Hendrikus Johannes Boele Chief Executive Officer, Managing Director 17 Dec 2025
Dr Anton Uvarov Executive Director 2 Apr 2024
Mr Brian Willoughby Leedman Non-Executive Chairman, Non-Executive Director 15 Dec 2023
Dr Raphael Bernier Non-Executive Director 8 Sep 2026

BlinkLab Limited (BB1) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
10 Sep 2026 UVAROV, Anton Exercise Options 2,000,000 $0.169 $338,000.000
10 Sep 2026 UVAROV, Anton Buy Indirect Shares 1,352,000 $0.250 $338,000.000
10 Sep 2026 LEEDMAN, Brian Buy Indirect Shares 1,521,000 $0.370 $562,500.000

See all changes in directors' interest & trades for BlinkLab Limited (BB1) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

BB1 Management

Name Position
Sebastiaan K.E. Koekkoek Chief Scientific Officer
Cornelis Pieter Boele Chief Technology Officer
Christopher (Chris) Bryan Achurch Company Secretary

BB1 Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in BlinkLab Limited (BB1). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
9,316,667 (6.09%) Yulia Uvarova

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.